Palisade Bio (PALI)
Develops a once-daily oral PDE4 prodrug for ulcerative colitis and Crohn's disease.
$1.61
vs last close−0.08 (−4.73%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 99.64% | 173.64M shares | |
|---|---|---|---|
| 126 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 2.24% | 3.91M shares | |
| 7 holders · as of Aug 21, 2026 | |||
| Strategic holders | 8.54% | 14.89M shares | |
| 1 holder · as of Dec 8, 2025 | |||
| Adds to | 110.42% | ||
174.27M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 110.42%; nothing is left for Other.
13F, as of Jun 30, 2026
126 holders · 173.64M shares · 53 new positions · 86 increased · 24 reduced · 22 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Soleus Capital Management, L.P. | 13.06M | 7.50% | +13.06Mnew | Aug 11, 2026 |
| B Group, Inc. | 11.41M | 6.55% | 0 | Aug 14, 2026 |
| Ameriprise Financial Inc | 11.08M | 6.36% | −428.9K | Aug 14, 2026 |
| Jupiter Topco LLC | 10.69M | 6.13% | +10.69Mnew | Aug 14, 2026 |
| BlackRock, Inc. | 10.44M | 5.99% | +8.56M | Aug 7, 2026 |
| Octagon Capital Advisors LP | 10.28M | 5.90% | 0 | Aug 14, 2026 |
| Perceptive Advisors LLC | 8.43M | 4.83% | −503.1K | Aug 14, 2026 |
| Ra Capital Management, L.P. | 7.12M | 4.09% | 0 | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Janus Henderson Group PLC | 9.99% | 14.89M | 13G | Dec 8, 2025 |
| Armistice Capital, LLC | 9.99% | 13G | May 15, 2025 | |
| Steven Boydincl. Armistice Capital, LLC | 9.99% | Nov 14, 2024 | ||
| RA Capital Management, L.P. | 9.90% | 17.62M | 13G | May 15, 2026 |
| Perceptive Advisors LLC | 7.90% | 14.11M | 13G | May 15, 2026 |
| Commodore Capital LP | 7.20% | 12.37M | 13G | May 15, 2026 |
| Octagon Capital Advisors LP | 6.40% | 9.57M | 13G | Feb 10, 2026 |
| BlackRock, Inc. | 6.00% | 10.44M | 13G | Jul 29, 2026 |
| Franklin Resources, Inc. | 6.00% | 9.16M | 13G | Jan 29, 2026 |
| Soleus Capital Master Fund, L.P. | 5.40% | 9.35M | 13G | May 27, 2026 |
| Ameriprise Financial, Inc. | 5.30% | 8.71M | 13G | May 15, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 8, 2026 | Robert Jr. Balteradirector | Purchase | 20,000 | $1.99 | 436,904 |
| Jul 9, 2026 | Robert Jr. Balteradirector | Purchase | 25,000 | $1.96 | 461,904 |
| Jul 7, 2026 | John David Finleydirector, officer: CEO, CFO | Sale | 146,798 | $2.07 | 217,555 |
| Jul 7, 2026 | Mitchell Lawrence Jonesofficer: Chief Medical Officer | Sale | 51,880 | $2.05 | 94,009 |
| Jul 6, 2026 | Robert Jr. Balteradirector | Purchase | 20,000 | $2.05 | 386,904 |
| Jul 7, 2026 | Robert Jr. Balteradirector | Purchase | 30,000 | $2.03 | 416,904 |
| Jul 1, 2026 | Robert Jr. Balteradirector | Purchase | 20,000 | $1.98 | 356,904 |
| Jul 2, 2026 | Robert Jr. Balteradirector | Purchase | 10,000 | $1.98 | 366,904 |
| Feb 12, 2026 | John David Finleydirector, officer: CEO, CFO | Sale | 3,896 | $1.75 | 27,353 |
| Feb 12, 2026 | Mitchell Lawrence Jonesofficer: Chief Medical Officer | Sale | 1,989 | $1.75 | 13,263 |
House and Senate disclosures
Not reported.